ORLADEYO® (berotralstat) can help you prevent hereditary angioedema (HAE) attacks

ORLADEYO provides meaningful and long-lasting HAE attack prevention

In a 3-part study of 120 adolescents and adults with HAE, 40 were given ORLADEYO 150 mg, 41 were given ORLADEYO 110 mg, and 39 were given placebo.

People taking ORLADEYO 150 mg for 6 months (part 1) had a 44% decrease in attack rate compared with people taking placebo (from 3.1 to 1.3 attacks per month for those taking ORLADEYO and from 2.9 to 2.4 attacks per month for those taking placebo).

Among 21 people who took ORLADEYO 150 mg for a total of 24 months (attacks before treatment: 2.8 per month), their average number of attacks per month dropped considerably.a

aThis reflects an ad hoc analysis of interim data (the trial investigators explored this trend after the trial was designed and before the final data analysis).

bAt 24 months, average attack rate was lowered by 86% compared with pretreatment for the 21 people who completed the full 24 months of treatment with ORLADEYO 150 mg.

cThese data are from an ad hoc analysis of the first 6 months of the study (part 1).

dBased on data on file from BioCryst Pharmaceuticals, Inc.